Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Other · Chemical/toxin
- Reported indication
- Not recorded
- First approval
- 1982
- Development stage
- Not recorded
- ChEMBL record
- CHEMBL1140 ↗
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Freederm; Niacinamid; Niacinamide; Niacinamide component of tpn; Niacinamide component of vitaped; Niacin (as niacinamide); Niatin; Nicam; Nicobion; Nicotinamida; Nicotinamide; Nicotinamidum; NSC-13128; NSC-27452; Papulex
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatOtherSprague-Dawley (transgenic)FemalePost-injury (acute); 8 weeks treatment (chronic)
Model: Acute peripheral (sciatic) nerve injury for post-traumatic axonal degeneration; chronic CMT1A Pmp22 transgenic model
Nicotinamide transiently delayed acute post-traumatic axonal degeneration but did not reduce chronic axonal loss in the CMT1A rat, unlike the Wlds transgene.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
RatChemical/toxinWistarMale500 mg/kg body weightSingle dose given either before or after acetaminophen intoxication
Model: Acute liver injury induced by an acetaminophen overdose of 5 g/kg body weight
Nicotinamide given after intoxication significantly ameliorated acetaminophen-induced biochemical changes and hepatic pathology, but the same dose given to healthy animals or before intoxication was itself hepatotoxic.
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
